At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 754 target
Drug / intervention
RMC-6236drug
Likely dose
Not stated in record
Key inclusion· 4
- ✓Histologically confirmed advanced solid tumor
- ✓KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion)
- ✓PDAC with wild-type RAS (expansion)
- ✓Treatment naive or prior standard therapy appropriate for tumor type and stage
Key exclusion· 4
- ✕Primary central nervous system (CNS) tumors
- ✕Active, untreated brain metastases
- ✕Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb oral medication
- ✕Unstable or clinically significant concurrent medical condition affecting safety, survival, or protocol compliance
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
In Brief
A Phase 2 clinical trial evaluating RMC-6236 for Non-small Cell Lung Cancer (NSCLC) and 3 related conditions. Currently recruiting, targeting 754 participants across 21 sites.
Signals
Enrolling ahead of pace
Detailed Summary
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 2Recruiting
20232024202520262027
First PostedMay 2022
Enrollment StartMay 2022
TodayJul 2026
Primary CompletionMay 2027
Study CompletionJul 2027
First PostedMay 18, 2022
Enrollment StartMay 31, 2022
Primary CompletionMay 31, 2027
Study CompletionJul 26, 2027
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 4.1 years agoPrimary completion in 11 months
Interventions
RMC-6236drug
Oral Tablets